Compare HOV & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOV | EOLS |
|---|---|---|
| Founded | 1959 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 592.5M | 500.0M |
| IPO Year | 1994 | 2018 |
| Metric | HOV | EOLS |
|---|---|---|
| Price | $104.65 | $7.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 106.9K | ★ 669.7K |
| Earning Date | 12-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $2,978,581,000.00 | $297,176,000.00 |
| Revenue This Year | N/A | $12.44 |
| Revenue Next Year | $4.52 | $17.37 |
| P/E Ratio | $64.32 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $90.17 | $3.86 |
| 52 Week High | $148.48 | $9.31 |
| Indicator | HOV | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 44.48 |
| Support Level | $90.85 | $6.99 |
| Resistance Level | $118.46 | $7.28 |
| Average True Range (ATR) | 5.67 | 0.35 |
| MACD | 1.20 | 0.02 |
| Stochastic Oscillator | 91.47 | 38.71 |
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.